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Disclaimer: Due to the rapidly evolving nature of this 
outbreak, and in the interests of rapid dissemination of 
reliable, actionable information, this paper went through 
expedited peer review. Additionally, information should be 
considered current only at the time of publication and may 
evolve as the science develops. 
To the Editor:
We are honored to have our systematic review of 
remdesivir for the treatment of COVID-19 published in the 
Western Journal of Emergency Medicine.1 Recently, new 
studies regarding the use of remdesivir have prompted us to 
submit this letter. On April 10, Grein et al reported that most 
patients given remdesivir in an open-label program exhibited 
observable clinical improvement.2 However, Wang et al did 
not find a statistically significant benefit with remdesivir 
in a randomized, double-blind, placebo-controlled trial of 
237 patients that was published on April 29.3 On the same 
day, a press release by the National Institute of Allergy 
and Infectious Diseases (NIAID) regarding the Adaptive 
COVID-19 Treatment Trial (ACTT) reported significantly 
reduced time to recovery and mortality with remdesivir.4 
Therefore, the purpose of our letter is to briefly analyze these 
new findings and determine whether additional conclusions 
in remdesivir’s treatment of COVID-19 can be drawn.
Grein et al analyzed open-label data from 61 patients 
who were treated with remdesivir between January–March 
2020. Patients were administered a loading dose of 200 
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milligrams (mg) on the first day followed by nine days 
of 100 mg infusions. Clinical improvement was based on 
a six-point scale: 1 = not hospitalized; 2 = hospitalized 
but not requiring supplemental oxygen; 3 = hospitalized 
and requiring supplemental oxygen; 4 = hospitalized and 
requiring nasal high-flow oxygen therapy, noninvasive 
mechanical ventilation or both; 5 = hospitalized requiring 
mechanical ventilation, extracorporeal membrane oxygen, 
or both. Most patients (68%) exhibited clinical improvement 
and 84% were discharged or showed a decrease of two 
points or more at follow-up. In total, 13% died and 60% 
exhibited adverse events, most commonly hepatic and renal 
dysfunction. Although these findings are encouraging, the 
small sample size, lack of a comparison group, case-by-
case variation in supportive care, and missing data make it 
difficult to draw robust conclusions.
The first randomized, controlled clinical trial of 
remdesivir for treatment of COVID-19 was published in 
The Lancet on April 29. This study analyzed treatment of 
237 patients (158 given remdesivir and 79 given placebo). 
Although the remdesivir group showed a reduced time to 
clinical improvement (18 vs 23 days), this was statistically 
insignificant. Neither mortality (14% vs 13%) nor adverse 
events (66% vs 64%) were commonly associated with 
remdesivir. The most common complications included 
constipation, hypoalbuminemia, hypokalemia, and anemia. 
However, there are several limitations to these results. 
Firstly, patients in the remdesivir and placebo groups 
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received interferon alfa (29% vs 38%), lopinavir-ritonavir 
(28% vs 29%), antibiotics (90% vs 94%), and corticosteroids 
(65% vs 68%) before and after enrollment. These additional 
drugs make it difficult to differentiate between the effects 
of remdesivir and other treatments. Moreover, the placebo 
group received a higher percentage of these drugs. Secondly, 
36 patients discontinued treatment due to adverse events, 
reducing the sample size. Since the trial was terminated early 
on March 29, the statistical power was reduced from 80% 
to 58%. Though these findings do not support remdesivir to 
treat COVID-19, the methodological limitations, missing 
data, and early termination moderate the results.
The ACTT is an ongoing randomized, double-blinded 
controlled trial of remdesivir that began enrolling on February 
21.5 After, the data and safety monitoring board performed 
a preliminary analysis of 1063 patients, the NIAID reported 
on April 29 that remdesivir statistically significantly reduced 
time to recovery compared to placebo (11 vs 15 days, 
p<0.001). There was also a modest increase in survival (8.0% 
vs 11.6%), which approached statistical significance (p = 
0.059). Although preliminary findings released by NIAID 
are supportive, it remains possible that the final results may 
differ at the conclusion of the trial. Also, the press release 
did not reveal any data about adverse events, loss to follow-
up, or other complications. Nevertheless, on May 1, based 
on the ACTT and Gilead open-label trial, the US Food and 
Drug Administration issued an Emergency Use Authorization 
(EUA) for use of remdesivir for COVID-19.2,4,6 Physicians 
may find it difficult to make informed decisions regarding 
treatment of patients with COVID-19. Given the recent EUA, 
we recommend making the decision to administer remdesivir 
based on the highest quality of evidence in the literature, 
which suggests decreased time to recovery and the possibility 
of increased survival.
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